중등도 이상의 만성폐쇄성폐질환 환자에서 흡입용 기관지확장제와 흡입용 기관지확장제/스테로이드 병합요법의 효과 및 안전성 평가
Efficacy and Safety of Inhaled Bronchodilator Versus Inhaled Bronchodilator/Inhaled Corticosteroid in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : According to the treatment guidelines for Chronic Obstructive Pulmonary Disease (COPD), long-acting β2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) are recommended. Addition of inhaled corticosteroid (ICS) is more effective in reducing acute exacerbations in patients with exacerbations and moderate to very severe COPD, but some studies have shown that it could increase the risk of pneumonia. Therefore, this study was conducted to evaluate the efficacy and safety of LABA/LAMA versus LABA/LAMA/ICS. Methods : Between January 2016 and June 2017, medical records of patients with moderate to severe COPD who visited the Department of Pulmonology in one hospital and started using LABA/LAMA (dual therapy) or LABA/LAMA/ICS (triple therapy) were reviewed retrospectively. The efficacy between in the two groups was evaluated as the number of acute exacerbations and change in pulmonary function. We also analyzed adverse drug reactions including pneumonia. Results : A total of 53 patients received dual therapy and 47 patients received triple therapy. The rate of acute exacerbations was reduced and change in FEV1 (Forced expiratory volume for 1 second) was improved in each group, but there was no difference between the two groups. Pneumonia occurred in 7.5% of patients receiving dual therapy versus 4.3% of patients receiving triple therapy, and other adverse drug reactions occurred in 11.3% of patients receiving dual therapy versus 4.3% of patients receiving triple therapy. Conclusion : Reduction in the rate of acute exacerbations in the triple therapy group was not significantly better than that in the dual therapy group, but adverse drug reactions, including pneumonia also did not show a difference between the two groups.
Abstract
Background : According to the treatment guidelines for Chronic Obstructive Pulmonary Disease (COPD), long-acting β2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) are recommended. Addition of inhaled corticosteroid (ICS) is more effective in reducing acute exacerbations in patients with exacerbations and moderate to very severe COPD, but some studies have shown that it could increase the risk of pneumonia. Therefore, this study was conducted to evaluate the efficacy and safety of LABA/LAMA versus LABA/LAMA/ICS. Methods : Between January 2016 and June 2017, medical records of patients with moderate to severe COPD who visited the Department of Pulmonology in one hospital and started using LABA/LAMA (dual therapy) or LABA/LAMA/ICS (triple therapy) were reviewed retrospectively. The efficacy between in the two groups was evaluated as the number of acute exacerbations and change in pulmonary function. We also analyzed adverse drug reactions including pneumonia. Results : A total of 53 patients received dual therapy and 47 patients received triple therapy. The rate of acute exacerbations was reduced and change in FEV1 (Forced expiratory volume for 1 second) was improved in each group, but there was no difference between the two groups. Pneumonia occurred in 7.5% of patients receiving dual therapy versus 4.3% of patients receiving triple therapy, and other adverse drug reactions occurred in 11.3% of patients receiving dual therapy versus 4.3% of patients receiving triple therapy. Conclusion : Reduction in the rate of acute exacerbations in the triple therapy group was not significantly better than that in the dual therapy group, but adverse drug reactions, including pneumonia also did not show a difference between the two groups.
참고문헌 (14)
- "COPD Clinical Practice Guidelines" (2018)[URL]
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, "Global Initiative for Chronic Obstructive Lung Disease", ~ (2018)
- Lipson DA, "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD", The New England journal of medicine, 378(18), pp.1671~1680 (2018)
- Papi A, "Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease(TRIBUTE) : a double-blind, parallel group, randomised controlled trial", Lancet(London, England), 391(10125), pp.1076~1084 (2018)
- Yang IA, "Inhaled corticosteroids for stable chronic obstructive pulmonary disease", The Cochrane database of systematic reviews, (7), pp.Cd002991~ (2012)
- Crim C, "Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation : The SUMMIT trial", Respiratory medicine, 131, pp.27~34 (2017)
- Bafadhel M, "Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease : a post-hoc analysis of three randomised trials", The Lancet Respiratory medicine, 6(2), pp.117~126 (2018)
- Kerkhof M, "Blood eosinophil count and exacerbation risk in patients with COPD", The European respiratory journal, 50(1) (2017)
- Cheng SL, "Blood eosinophils and inhaled corticosteroids in patients with COPD : systematic review and meta-analysis", International journal of chronic obstructive pulmonary disease, 13, pp.2775~2784 (2018)
- Oh YM, "Blood eosinophil count as a prognostic biomarker in COPD", International journal of chronic obstructive pulmonary disease, 13, pp.3589~3596 (2018)
- Yun JH, "Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease", The Journal of allergy and clinical immunology, 141(6), pp.2037~2047 (2018)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, "Global Initiative for Chronic Obstructive Lung Disease", ~ (2019)
- Watz H, "Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids : a post-hoc analysis of the WISDOM trial", The Lancet Respiratory Medicine, 4(5), pp.390~398 (2016)
- Oshagbemi OA, "Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD : Systematic Review and Meta-analysis", Current Drug Targets, 20(16), pp.1670~1679 (2019)